ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1751

Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study

Gregory McDermott1, Xiaosong Wang2, Misti Paudel3, Ying Qi4, Emily Kowalski5, Grace Qian6, Liya Sisay Getachew5, Kevin Mueller6, Alene Saavedra6, Lauren O'Keeffe6, Natalie Davis1, Alison Puri7, Kathleen Vanni6, Caleb Bolden8, Tina Mahajan9, Erica Mulcaire-Jones10, Neda Kortam11, Pierre Antoine Juge12, Tracy J. Doyle13, Marcy Bolster14, Kevin Deane15, Dinesh Khanna10, Bryant England9, Raul San Jose Estepar6, George Washko6 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Brookline, MA, 2Brigham and Women's Hospital, Natick, MA, 3Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 4Brigham and Women’s Hospital, Boston, 5Brigham and Women's Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, 7Boston University, Brookline, MA, 8Massachusetts General Hospital, Boston, 9University of Nebraska Medical Center, Omaha, NE, 10University of Michigan, Ann Arbor, MI, 11University of Michigan, Ann Arbor, 12Hopital Bichat, APHP, Paris, France, 13Brigham and Women's Hospital, West Roxbury, MA, 14Massachusetts General Hospital, Concord, MA, 15University of Colorado Denver Anschutz Medical Campus, Aurora, CO

Meeting: ACR Convergence 2025

Keywords: Computed tomography (CT), Imaging, interstitial lung disease, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes I: Breathe (ILD/Pulmonary) (1746–1751)

Session Type: Abstract Session

Session Time: 11:15AM-11:30AM

Background/Purpose: Quantitative computed tomography (QCT) methods using machine learning have been developed to automatically quantify parenchymal lung features on chest CT imaging. QCT can detect subtle or early abnormalities, and abnormal QCT findings have been associated with symptoms, progressive lung disease, and mortality in general population studies. Based on prior studies linking RA disease activity to interstitial lung disease (ILD) in patients with established RA, we hypothesized that higher RA disease activity would be associated with increased interstitial changes on QCT in early RA.

Methods: We performed a cross-sectional study of participants in SAIL-RA (Study of Inflammatory Arthritis and ILD in Early RA), an ongoing prospective, multicenter longitudinal study of patients recently diagnosed with RA at five U.S. sites between 2017 and 2025. All participants had early RA (diagnosed < 2 years prior to enrollment) and were assessed with physical examination, chest high-resolution CT imaging, pulmonary function tests (PFTs), and peripheral blood testing. QCT was performed using a k-nearest neighbor machine learning classifier that categorizes regions of interest into normal lung, interstitial changes, or emphysema based on the local tissue density and distance from the pleural surface. Interstitial changes on QCT may represent features of ILD or other abnormalities such as scarring after infection. We examined the correlation of QCT interstitial changes with PFTs, RA disease activity, and erythrocyte sedimentation rate (ESR) using Spearman correlation coefficients. We tested the association between baseline age, sex, smoking status, RF, anti-CCP, and RA disease activity with QCT interstitial features using multivariable linear regression.

Results: We performed chest QCT analysis on 200 participants with early RA (median RA duration 0.72 years, mean age 55.7 years, 75% female, 85% seropositive) (Table 1). On QCT, early RA patients had mean normal lung percentage of 88.0% (SD 7.8). The mean percentage of interstitial changes and emphysema was 5.6% (SD 6.8) and 1.2% (SD 1.7), respectively. Interstitial changes on QCT were correlated with higher DAS28-ESR (rho=0.26, p=0.0003) and ESR (rho=0.30, p< 0.0001), as well as lower FVC% (rho=-0.23, p=0.002) and DLCO% (rho=0.42, p< 0.0001) (Figure 1). In a multivariable linear regression model, older age (b=+0.14 per year, 95%CI 0.07-0.21, p< 0.0001) and DAS28-ESR (b=0.64 per point, 95%CI 0.01-1.26, p=0.046) were independently associated with percentage of interstitial changes (Table 2). The b from the linear regression model can be interpreted as a percentage increase in interstitial changes per unit increase in the predictor (increase of 0.70% per point of DAS28-ESR).

Conclusion: In this prospective, multicenter study of 200 patients with early RA analyzed using machine learning QCT methods, older age and higher RA disease activity were associated with more QCT interstitial changes. QCT interstitial changes were correlated with lower FVC and DLCO. These findings emphasize the role of inflammation in RA-ILD pathogenesis early in the RA disease course and demonstrate the potential of QCT for RA-ILD screening and monitoring.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. McDermott: None; X. Wang: None; M. Paudel: None; Y. Qi: None; E. Kowalski: None; G. Qian: None; L. Getachew: None; K. Mueller: None; A. Saavedra: None; L. O'Keeffe: None; N. Davis: None; A. Puri: None; K. Vanni: None; C. Bolden: None; T. Mahajan: None; E. Mulcaire-Jones: Caribou Pharmaceuticals, 2; N. Kortam: AstraZeneca, 5; P. Juge: None; T. Doyle: Bayer, 5, Sanofi, 3; M. Bolster: Genentech, 5, Mitsubishi, 5, Prometheus, 5; K. Deane: Inova Diagnostics, 1; D. Khanna: Argenx, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Novartis, 2, UCB, 2, Zura Bio, 2; B. England: Boehringer-Ingelheim, 2, 5; R. Estepar: Boehringer-Ingelheim, 5, Gossamer Bio, 5, Lung Biotechnology, 7, Quantitative Imaging Solutions, 12,; G. Washko: Apogee, 2, AstraZeneca, 2, Boehringer-Ingelheim, 5, Intellia Therapeutics, 2, Pieris Therapeutics, 2, Quantitative Imaging Solutions, 12,, Regeneron, 2, Sanofi, 2, Verona, 1, 2; J. Sparks: Boehringer Ingelheim, 5, Bristol-Myers Squibb (BMS), 5, Janssen, 5.

To cite this abstract in AMA style:

McDermott G, Wang X, Paudel M, Qi Y, Kowalski E, Qian G, Getachew L, Mueller K, Saavedra A, O'Keeffe L, Davis N, Puri A, Vanni K, Bolden C, Mahajan T, Mulcaire-Jones E, Kortam N, Juge P, Doyle T, Bolster M, Deane K, Khanna D, England B, Estepar R, Washko G, Sparks J. Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/disease-activity-inflammation-and-older-age-are-associated-with-quantitative-interstitial-abnormalities-in-early-ra-results-from-a-multicenter-prospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-inflammation-and-older-age-are-associated-with-quantitative-interstitial-abnormalities-in-early-ra-results-from-a-multicenter-prospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology